Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 693.35

-0.2%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Felix B who wrote (2578)	11/8/2018 3:03:02 AM
From: Miljenko Zuanic	of 3559

It is not that REGN IP is bad (except praluent case), it is that other-competitor IP is strong! So, REGN does not have choice other than to do license 'class" for royalty. Tuck think (and he is right) that at least REGN know what to license or have something to license due to marketing restriction...it is my view that their "front-line" science is not actually "front-line"! So far they are very good with me-too drug (even with anti IL-4/13), and as long as it works...I am fine (as SH) with it.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next